Cargando…

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

INTRODUCTION: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raterman, Hennie G, Vosslamber, Saskia, de Ridder, Sander, Nurmohamed, Michael T, Lems, Willem F, Boers, Maarten, van de Wiel, Mark, Dijkmans, Ben AC, Verweij, Cornelis L, Voskuyl, Alexandre E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446469/ https://www.ncbi.nlm.nih.gov/pubmed/22540992 http://dx.doi.org/10.1186/ar3819

Ejemplares similares

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab
por: de Jong, Tamarah D, et al.
Publicado: (2015)

Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters
por: de Jong, Tamarah D., et al.
Publicado: (2016)

Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome
por: Raterman, Hennie G, et al.
Publicado: (2009)

A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks
por: den Uyl, Debby, et al.
Publicado: (2014)

Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide
por: Raterman, Hennie G., et al.
Publicado: (2019)

Moving towards personalized medicine in rheumatoid arthritis
por: de Jong, Tamarah D, et al.
Publicado: (2014)

(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis
por: den Uyl, Debby, et al.
Publicado: (2011)

Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study
por: van Halm, Vokko P, et al.
Publicado: (2006)

Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET
por: Verweij, Nicki, et al.
Publicado: (2022)

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients
por: Bruijnen, Stefan, et al.
Publicado: (2016)

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
por: van Sijl, Alper M., et al.
Publicado: (2014)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

Common mechanisms and holistic care in atherosclerosis and osteoporosis
por: Szekanecz, Zoltán, et al.
Publicado: (2019)

Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review
por: Elbers, Laura P. B., et al.
Publicado: (2021)

Combining DNA-microarray data in systemic lupus erythematosus
por: Verweij, Cornelis L, et al.
Publicado: (2011)

Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review
por: van Tuyl, Lilian HD, et al.
Publicado: (2014)

An unfavorable body composition is common in early arthritis patients: A case control study
por: Turk, Samina A., et al.
Publicado: (2018)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Content validity of the Dutch Rheumatoid Arthritis Impact of Disease (RAID) score: results of focus group discussions in established rheumatoid arthritis patients and comparison with the International Classification of Functioning, Disability and Health core set for rheumatoid arthritis
por: ter Wee, Marieke M., et al.
Publicado: (2016)

The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes
por: de Jong, Tamarah D., et al.
Publicado: (2016)

Outcome measures for adherence data from a medication event monitoring system: A literature review
por: Hartman, Linda, et al.
Publicado: (2018)

One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy
por: Lems, Willem F, et al.
Publicado: (2016)

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial
por: Boers, Maarten, et al.
Publicado: (2022)

Endothelial Dysfunction, Inflammation, and Apoptosis in Diabetes Mellitus
por: van den Oever, Inge A. M., et al.
Publicado: (2010)

Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis
por: de Jong, Tamarah D., et al.
Publicado: (2019)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count
por: Hartman, Linda, et al.
Publicado: (2021)

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients
por: van Baarsen, Lisa G. M., et al.
Publicado: (2008)

Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice
por: Eekman, Danielle A, et al.
Publicado: (2011)

Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial
por: Lucassen, M. J. J., et al.
Publicado: (2021)

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases
por: de Jong, Tamarah D., et al.
Publicado: (2016)

Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis
por: Schmidt, Brian J, et al.
Publicado: (2013)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Favourable effect of a ‘second hit’ after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial
por: Hartman, Linda, et al.
Publicado: (2022)

Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates
por: Eekman, Danielle A, et al.
Publicado: (2009)

Osteopenia: A Diagnostic and Therapeutic Challenge
por: Lems, Willem F., et al.
Publicado: (2011)

Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study
por: Gent, Yoony Y. J., et al.
Publicado: (2015)

Microvascular function is preserved in newly diagnosed rheumatoid arthritis and low systemic inflammatory activity
por: van Eijk, Izhar C., et al.
Publicado: (2011)

Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rbm8m8bkgc97l97gop59jlt1ug